Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review by Edwards, CJ et al.
Original article
Predicting disease progression and poor outcomes
in patients with moderately active rheumatoid
arthritis: a systematic review
Christopher J. Edwards1, Patrick Kiely2, Subhashini Arthanari3,
Sandeep Kiri4,a, Julie Mount5, Jane Barry6,b, Catherine R. Mitchell7,c,
Polly Field7 and Philip G. Conaghan8
Abstract
Objectives Access to biologic DMARDs for RA is often restricted to those with severe disease. This
systematic review aimed to identify prognostic factors in patients with moderate disease activity who
may be at risk of disease progression and poor clinical outcomes.
Methods MEDLINE, Embase and Cochrane databases were searched (final search 22 September
2017), and data from patients with moderate disease [28-joint DAS (DAS28) >3.2–5.1] were included.
Studies were evaluated according to the measure(s) of progression/poor outcome used: radiographic,
disease activity or other indicators.
Results The searches identified 274 publications, of which 30 were selected for data extraction.
Fourteen studies were prioritized, because they specifically analysed patients with moderate RA.
Nine studies reported radiographic progression outcomes for 3241 patients, three studies reported
disease activity progression for 1516 patients, and two studies reported other relevant outcomes
for 2094 patients. Prognostic factors with consistent evidence for progression/poor outcome
prediction were as follows: DAS28 4.2, the presence of anti-CCP antibodies, and power Doppler
ultrasound score 1. Some predictors were specific to either disease activity or radiographic
progression.
Conclusion Several criteria used in standard clinical practice were identified that have the potential
to inform the selection of patients with moderate RA who are at greater risk of a poor outcome. A
combination of two or more of these factors might enhance their predictive potential. Further work is
required to derive clinical decision rules incorporating these factors.
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Introduction
It is estimated that 47–53% of patients with early RA
(<12months since diagnosis) develop moderate to se-
vere disease over 5 years [1], where moderate disease is
defined as a 28-joint DAS (DAS28) of >3.2–5.1, and
severe disease as a DAS28>5.1 [2]. Although moder-
ately active RA is common, studies aiming to predict RA
progression have largely included patient populations
with early and severe RA [3].
Treatments for RA include conventional synthetic
DMARDs (csDMARDs), biologic DMARDs (bDMARDs) and,
more recently, targeted synthetic DMARDs (tsDMARDs).
EULAR guidelines recommend that bDMARDS are used
only in patients with poor prognostic factors, including
moderate to severe disease, after the failure of one or
more csDMARDs [4]. In England and Wales, the National
Institute for Health and Care Excellence recommends that
approved bDMARDs should be used for RA only when the
disease activity is severe and has not responded to inten-
sive therapy with a combination of csDMARDs [5].
Australian guidelines state that established severe or per-
sistent disease must be present, or the patient should have
had previous unsuccessful treatment with at least two
csDMARDs [6]. These guidelines require patients to receive
multiple csDMARDs before treatment with biologics. These
requirements for high disease activity do not address the
issue that many people with a moderate DAS may have
disease progression, and therefore optimal treatment, for
example, the use of bDMARDs, may be necessary for
these individuals. The aim of this systematic literature re-
view was to identify prognostic factors in patients with RA
with moderately active disease who were at greater risk of
progression and who had poor clinical outcomes.
Methods
Search strategy
MEDLINE, MEDLINE In-Process & Other Non-Indexed
Citations, Embase and Cochrane Library databases were
searched via Ovid on 27 October 2016 (final search 22
September 2017). The search strings and number of
sources found are provided in Supplementary Table S1,
available at Rheumatology Advances in Practice online.
Inclusion criteria were limited to English-language publica-
tions, and no date restrictions were applied. Supplementary
searches to identify relevant congress abstracts are outlined
in Table 1. Abstracts and posters were screened online,
and the bibliographies of eligible systematic reviews and
meta-analyses were searched manually for relevant publica-
tions. Conference abstracts were included even if no sub-
sequent publication was found, in order to capture as
many data sources as possible.
Citation screening, full text review and data
extraction
One analyst screened the title and abstract of the re-
trieved references to determine whether they met the pre-
defined eligibility criteria (Table 2); any uncertainties were
resolved by a second analyst. Publications that met the
inclusion criteria were re-assessed against the review cri-
teria. Data were extracted into predefined data summary
tables and checked by a second independent analyst.
Definitions of progression
We used several progression outcomes. These are sum-
marized across three categories (radiographic progres-
sion, disease activity progression and other) in
Supplementary Table S2, available at Rheumatology
Advances in Practice online. A well-established way of
measuring structural disease progression is achieved by
radiographic assessment. Most studies used the van
der Heijde–Sharp (vdHS) score (a minimum increase of
one, three or five units, although not consistent across
studies). Some used other radiographic scores, such as
the Larsen or Ratingen score, or MRI scores. These are
described in detail in Supplementary Table S3, available
at Rheumatology Advances in Practice online.
Disease activity progression was typically defined us-
ing standard DAS28 thresholds (remission, <2.6; low,
3.2; moderate, >3.2–5.1; severe, >5.1). Some stud-
ies used a Health Outcomes Questionnaire (HAQ) to de-
fine progression in disability. Full details for each study
are presented in Supplementary Table S4, available at
Rheumatology Advances in Practice online. The ‘other
outcomes’ category included surrogate factors, such as
initiation of biologics or the requirement for major joint
surgery, alongside more standard health-related quality
of life measures. Full details of the studies in this cate-
gory are provided in Supplementary Table S5, available
at Rheumatology Advances in Practice online.
Results
Search results
The database searches identified 2964 articles, 457 of
which were duplicates, leaving 2507 articles for
Key messages
. Three prognostic factors were identified in moderately active RA patients at greater risk of disease progression.
. DAS28 4.2, anti-CCP antibody presence and power Doppler ultrasound score 1 were identified as indicators
of potential progression.
. Higher-risk RA patients with moderate disease activity may benefit from more intensive treatment strategies.
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electronic screening; 2314 were excluded after applying
inclusion and exclusion criteria. Thus, 193 underwent full
review, and 47 were excluded. A further 128 relevant
congress abstracts were identified, giving 274 total
references that met the broad inclusion criteria. Details
are shown in the PRISMA flow diagram in Fig. 1.
Only studies that reported data from study popula-
tions with moderate disease activity were included,
allowing focus on the identification of markers for
greater risk of progression in patients with moderate RA.
Data from 30 sources [7–35] were extracted. We further
prioritized studies where the study population was ex-
plicitly limited to patients with moderate RA, leaving 14
prioritized sources [3, 7, 8, 10, 11, 14, 20–22, 24, 26–28,
31], and deprioritizing 16 studies [9, 12, 13, 15–19, 23,
25, 29, 30, 32–35] that had populations with mixed RA
disease activity. These deprioritized studies that
reported a mean DAS within the moderate range are
summarized in Supplementary Table S6, available at
Rheumatology Advances in Practice online.
Summary of prioritized moderate RA population
studies
Several potential prognostic markers for disease progres-
sion were examined across the 14 prioritized publications.
We summarized the evidence for the association between
these markers and each of the three categories of pro-
gression outcome: radiographic progression, disease ac-
tivity and functional progression or other progression
measures (initiation of biologics and need for joint sur-
gery) (Supplementary Table S2, available at
Rheumatology Advances in Practice online), and summa-
rized the prognostic markers investigated in each study
and the overall study outcome (Table 3).
Three prognostic factors were identified in moderately
active RA patients at greater risk of disease progression:
DAS28 4.2, the presence of anti-CCP antibodies and
power Doppler ultrasound score (PDUS)  1. These
thresholds are summarized in Table 4.
Radiographic progression
The factors below were assessed for their ability to pre-
dict radiographic progression, defined as changes in
vdHS score or Ratingen score, or increase in cartilage
damage. The methodology of the included radiographic
progression studies is shown in Supplementary Table S3,
available at Rheumatology Advances in Practice online,
and the results for each study are provided in
Supplementary Table S7, available at Rheumatology
Advances in Practice online.
Power Doppler ultrasound and grey scale ultrasound
Two studies, one Swiss (n¼ 377) and one Spanish
(n¼129), examined the prognostic value of PDUS in
moderate disease. In the Swiss study, patients had ra-
diographic damage to their hands appraised by a
blinded assessor. Forty-nine per cent of the study popu-
lation had received bDMARDs. Radiographic damage
progression was defined as an increase in the Ratingen
score (range 0–190; smallest detectable change 3.3
points). Twenty-two joints were assessed, with each
joint being scored from 0 to 3. Score thresholds of 6/66,
4/66 and 2/66 were used to define the worst 20, 30 and
50% of PDUS scores, respectively. Patients with scores
above these thresholds were significantly more likely to
experience radiographic progression over the 5-year fol-
low-up period (univariate analyses) [27].
In the Spanish study, radiographs of hands and feet
were scored according to vdHS scores. Radiographic
progression was assessed in 12 joints (scored 0–3), and
progression was defined as an increase of more than
one point. A PDUS score >1 at baseline was associated
with radiographic progression [odds ratio (OR), 5.067;
95% CI, 1.162, 21.576; P¼0.017], as was maintenance
of that score over 1 at 6months (OR, 7.474; 95% CI,
2.644, 21.123; P< 0.001) [14].
A similar result was found for grey scale ultrasound
(GSUS) damage scores, with two publications [one from
Switzerland (n¼ 377) [27] and one from the Netherlands
(n¼222) [31] in patients with moderate disease activity]
reporting that baseline damage scores could signifi-
cantly predict disease progression. The Swiss study
assessed 22 joints (scored from 0 to 3) and used GSUS
score thresholds of 18/66, 16/66 and 11/66 to define the
worst 20, 30 and 50% of GSUS scores, respectively.
A significantly higher proportion of patients (P< 0.05)
with a GSUS score greater than each of these thresh-
olds had radiographic progression over the 5 years of
follow-up (univariate analyses) [27].
In the Dutch study, patients were followed up for
24months and assessed using vdHS scores. Progression
was defined as an increase of more than one point per
year. In the multivariate model, RF positivity (OR, 2.27,
TABLE 1 Congress proceedings searched as part of the systematic review
Number Congress Congress month Proceedings available
at time of search
1 International Society for Pharmacoeconomics
and Outcomes Research (ISPOR), USA
May 2014–2017
2 ISPOR, Europe October/November 2014–2017
3 European League Against Rheumatism (EULAR) June 2014–2017
4 American College of Rheumatology (ACR) November 2014–2017
5 British Society for Rheumatology (BSR) conference April 2014–2017
Predicting progression and outcome in RA
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TABLE 2 Eligibility criteria for inclusion in the systematic review
Eligibility criteria
Population . Patients with active RA
. Moderate or severe stage (DAS28 >3.2)a
. Adults (aged 18 years)
Interventions . Any or no intervention (patients not treated with biologics were prioritized)
Outcomes Predictive or prognostic factors that may influence patient outcomes. Examples are listed below.
. Demographic markers
 Age, BMI, disease duration, sex, smoking status
. Clinical markers
 DAS
 Duration of morning joint stiffness
 Extra-articular manifestations
 HAQ score
 Joint erosion
 Patient VAS in DAS28
 Symmetrical polyarthritis
. Imaging markers
 Radiographic score at baseline
 MRI or ultrasound features at baseline
. Inflammatory markers
 CRP
 ESR
. Genetic markers
 PTPN22 gene
 HLA-DRB1 shared epitope
. Presence of autoantibodies
 Anti-CCP antibody
 Anti-peptidyl-arginine deiminase-4 antibody
 IgA RF
. Bone markers
 Cartilage oligomeric matrix protein
 Collagen cross-linked C-telopeptide
 Human cartilage glycoprotein-39
 MMP-3
 RANK ligand:osteoprotegerin ratio
The influence of these factors on the following patient outcomes was assessed
. HAQ (patient assessment of functional ability), arthritis impact measurement scales, McMaster–
Toronto arthritis questionnaire scores
. Radiographic progression
. Change in DAS or DAS28
. ACR 20/ACR 50/ACR 70 response
. EULAR response
. Remission
. Patient assessment of pain (using VAS or Likert scale)
. EQ-5D score
. Patient/physician assessment of disease activity (using VAS or Likert scale)
. Morning stiffness, number of flares
Study design . No restriction
Publication typeb . Primary
. Pooled data
. Systematic review and meta-analysis (included in order to search reference lists)
Date restriction . No date restriction
Language restriction . English only (non-English-language publications with an English abstract were considered for
inclusion)
Country . No restriction (European and US publications were prioritized)
aStudies that recruited only patients with moderate RA were prioritized at the final selection stage; therefore, studies with
a mixed RA population were deprioritized.
bGeneral narrative reviews, editorials, economic analysis and cost studies were excluded.
Abbreviations: ACR 20/50/70: 20%/50%/70% improvement in ACR criteria; DAS28: 28-joint DAS; EQ-5D: European quality
of life – five dimensions; VAS: visual analog scale.
Christopher J. Edwards et al.
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P¼ 0.022), total vdHS (OR, 1.08, P¼ 0.017) and GSUS
score (OR, 1.03 per point, P¼0.019) were independent
baseline predictors of radiographic progression at
24months [31].
Magnetic resonance imaging
MRI-detected inflammatory pathologies at baseline
(baseline radial osteitis, synovitis at the radioulnar, radio-
carpal and intercarpal–carpometacarpal joints) were
shown to be predictive for the Auckland cartilage score
after 3 years of follow-up (P< 0.005) in an MRI study of
patients with moderate RA (n¼28) [24].
vdHS score
Three studies examined the prognostic value of baseline
vdHS score as a marker of radiographic progression [3,
8, 31]. In an American prospective observational study
of 644 patients with moderate RA (95% DMARD naı¨ve),
baseline vdHS score was one of several markers that
were associated with radiographic progression, as
measured by changes in vdHS score at 2 years (OR,
1.01; 95% CI, 1.00, 1.01) [8]. Other markers were sero-
positivity for RF or anti-CCP antibody, duration of RA of
<2 years, below normal body weight and DAS28.
However, in a French study of 96 patients with moder-
ate RA, the baseline erosion score was not predictive of
significant radiographic progression (vdHS score >3.0
overall) over 3 years of follow-up [3]. In a Dutch study
(n¼222; methodology described above) [31], RF positiv-
ity (OR, 2.27; P¼ 0.022), total vdHS (OR, 1.08;
P¼0.017) and GSUS score (OR, 1.03 per point;
P¼0.019) were independent baseline predictors of ra-
diographic progression at 24months in a multivariate
model [31].
Antibody status
Antibodies were investigated as potential prognostic
markers for radiographic progression in several studies.
An American study in 644 patients with moderate RA
FIG. 1 PRISMA flow diagram
PRISMA: preferred reporting items for systematic reviews and meta-analyses.
Predicting progression and outcome in RA
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reported that seropositivity for either RF or anti-CCP an-
tibody at baseline predicted rapid radiographic progres-
sion, as measured by changes in vdHS score at 2 years
(OR, 3.35; 95% CI, 1.41, 7.99) [8]. Another American
study (n¼1309) found that anti-CCP antibodies at base-
line in patients with moderate disease predicted the de-
velopment of joint erosions (OR, 2.72; 95% CI, 1.77,
4.18) [7]. The presence of anti-CCP antibodies and ero-
sions (vs absence) was associated with a greater extent
of erosions/joint deformity and lower odds of remission
[7]. Two further studies report that patients with anti-
CCP antibodies had developed significantly more severe
radiological damage than those without [10, 21].
Biomarkers
A retrospective observational study reported that the
multi-biomarker disease activity (MBDA) score enhanced
the ability of conventional risk factors [i.e. serological
status, swollen joint count (SJC), CRP and DAS28-CRP
(modified DAS28 using CRP)] to predict radiographic
progression in patients with moderate RA receiving non-
biologic DMARDs [22].
Disease activity and functional progression
Factors assessed for their ability to predict progression
in disease activity (measured by DAS28 or HAQ score)
are detailed below. The methodology of these studies is
shown in Supplementary Table S4, available at
Rheumatology Advances in Practice online and the
results in Supplementary Table S8, available at
Rheumatology Advances in Practice online.
DAS28 at baseline
An assessment of the use of DAS28 at baseline was
performed in 418 patients with newly diagnosed RA
stratified by DAS28 (low, <3.2; low-moderate, 3.2–4.1;
high-moderate, 4.2–5.1; high >5.1) 1 year after presenta-
tion. The proportions of patients with a year 1 high-mod-
erate DAS28 who achieved DAS28<3.2 at year 2 (16%)
and year 3 (19%) were similar to the proportions of
patients with a year 1 high DAS28 (>5.1) who achieved
this outcome (13 and 15%, respectively). Patients with a
year 1 moderate DAS28 (3.2–5.1) were significantly less
likely to achieve a low HAQ score (<1.25) at year 2 than
those with a year 1 DAS28< 3.2 [20].
Anti-CCP antibody status
The presence of anti-CCP antibodies as a predictor of
disease activity progression was assessed in one multi-
national study (Canada, USA and UK) in patients with
moderate RA (n¼ 342) but reported that the presence of
anti-CCP antibodies did not predict disease progression
after 2 years, as measured by HAQ score, DAS28 or
SJC [10].
Other progression indicators
Other RA progression indicators are summarized below.
The methodology of the studies included in this cate-
gory is shown in Supplementary Table S5, available at
Rheumatology Advances in Practice online, and theT
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outcomes are detailed in Supplementary Table S9, avail-
able at Rheumatology Advances in Practice online.
Initiation of biologics
In a Canadian prospective observational study in 1146
patients with moderate RA, DAS28 at baseline was the
only independent factor predicting the initiation of bio-
logics, a proxy of disease progression, within 1 year
(OR, 1.48, P< 0.001) [11].
Requirement for joint surgery
An examination of the ability of baseline DAS28 to predict
whether joint surgery would be required within 5years in
a population with moderate RA (mean DAS28, 4.8) was
performed [28]. Patients with high-moderate (4.2–5.1,
n¼426) baseline DAS28 had a significantly higher risk of
requiring intermediate surgery (synovectomies and arthro-
plasties of wrist/hand or hind/forefoot) within 5 years than
those with low-moderate (>3.2–4.19, n¼522) or low
(>2.6–3.2) DAS28 [hazard ratio (HR), 1.80; 95% CI, 1.05,
3.11; P¼ 0.034]. Patients with low-moderate or high-
moderate DAS28 had a significantly higher risk of requir-
ing major surgery (defined as large joint replacements)
within 5 years than those with low DAS28 (HR, 2.07; 95%
CI, 1.28, 3.33; P< 0.005 and HR, 2.16; 95% CI, 1.32,
3.52; P< 0.005, respectively). The rate of such surgery at
5 years was significantly higher in patients with high-
moderate DAS (4.2–5.1) after 1 year than in those with
low DAS (>3.2–4.19; P< 0.05) [28].
Discussion
This review identified evidence supporting the use of
higher levels within the moderate DAS28 range
(DAS28>3.2–5.1), imaging (PDUS, GSUS or MRI),
anti-CCP antibody status and MBDA tests to identify
patients who are at greater risk of progression and
poorer clinical outcomes than other patients in this cate-
gory. It should be noted that a moderate DAS28 level
does not equate to a benign outcome, and these
patients may potentially benefit from more intensive
treatment strategies, because there is a low likelihood of
moderate patients achieving a low DAS28 with
csDMARDs [20]. Some of the identified progression
measures are already used routinely in the clinic, and
using the results for predicting prognosis should impose
a minimal implementation cost. Although MRI and
MBDA tests are not currently used in standard practice,
there is evidence of their value as prognostic factors.
In terms of radiographic progression, higher baseline
DAS28 within the moderate range was commonly
reported to predict poor outcomes [10, 20, 26]. In par-
ticular, higher moderate baseline DAS28 (range, 4.2–5.1)
was able to predict the requirement for intermediate
(synovectomies and arthroplasties of wrist/hand or hind/
forefoot) or major joint surgery within 5 years [28], and
patients with early moderate RA who did not achieve re-
mission after a year of DMARD treatment were very un-
likely to achieve remission within 3 years [20].
There is strong evidence that imaging results are prog-
nostic of radiographic progression, shown in six studies
[8, 14, 24, 27, 31]. The imaging results included PDUS
[14, 27] and GSUS scores [27, 31] and specific measures
of damage, such as baseline radial osteitis and synovitis
[24], in addition to vdHS [8]. The anti-CCP antibody was
significantly associated with severe radiological damage
after 6 years of follow-up, and RF or anti-CCP antibodies
at baseline were predictive of radiographic progression
[8]. The MBDA score enhanced the ability of conventional
risk factors (i.e. serological status, SJC, CRP and DAS28-
CRP) to predict radiographic progression [22].
This systematic review also assessed prognostic fac-
tors for disease activity progression. Patients with low or
low-moderate baseline DAS28 were more likely to
achieve a DAS28<3.2 over 2 years of follow-up, al-
though these findings are from a single study [20]. The
anti-CCP antibody was also significantly associated with
disease progression in one study [10].
Several studies suggested that the value of these
prognostic factors could be enhanced by using them in
combination. Fautrel et al. [3] concluded that high CRP
levels combined with RF positivity at baseline were a
strong indicator for radiographic progression at 2 and
3 years of follow-up. A mixed population study (depriori-
tized in this review) reported that DAS28 could be com-
bined with up to three risk factors (anti-CCP antibodies,
ESR and Ratingen score) to predict joint damage pro-
gression more accurately than DAS28 alone [15]. The
authors of both studies suggested that optimizing treat-
ment for patients with poor prognostic outcomes would
TABLE 4 Identified prognostic factors and reported thresholds for patients with moderate RA
Factor Threshold for progression Sources
DAS28 >4.2 at baseline Kiely et al., 2011 [20]
Nikiphorou et al., 2015 [28]
Presence of anti-CCP antibodies (Presence at baseline) Alemao et al., 2014 [8]
Alemao et al., 2016 [7]
Kroot et al., 2000 [21]
Barra et al., 2013 [10]
PDUS PDUS score 1 at baseline De Miguel et al., 2015 [14]
Abbreviations: DAS28: 28-joint DAS; PDUS: power Doppler ultrasound.
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include earlier intervention with bDMARDs. Further studies
are required to establish the sensitivity of these factors, ei-
ther alone or in combination, and to define which patients
would most benefit from earlier bDMARD intervention.
This systematic review has some limitations.
Publications were identified by searching for keywords,
such as ‘moderate’ and ‘predictor’, in the title and ab-
stract. Therefore, relevant publications that did not con-
tain these keywords might have been missed. Our
search identified publications that reported a median or
mean DAS28 in the moderate range, but in fact con-
sisted of mixed RA populations. Therefore, these might
include some outlying patients with mild or severe dis-
ease activity. We deprioritized these studies, halving the
potential number of publications available to analyse for
this review. More evidence might have been available
for populations with moderate disease, but if the publi-
cation did not report a baseline DAS28 value or did not
label the disease severity as ‘moderate’, the study
would not have been included for extraction.
Additionally, radiographic disease progression is demon-
strated in most of the studies using the Sharp van Der
Heijde score, with several different thresholds reported.
Some are below the minimally clinically relevant value
(typically five) and, as a result, a degree of caution is re-
quired in interpreting these studies. Finally, we were not
able to conduct any quantitative synthesis of the data,
because the progression measures, study designs and
markers explored were too heterogeneous.
In summary, several factors, potentially in combination,
can identify patients with moderate RA who are at risk of
disease progression and a poor clinical outcome. These
patients should be considered as candidates for escala-
tion of therapy to bDMARDs or tsDMARDs, using a treat-
to-target approach. The heterogeneity of studies found in
this systematic review showed that there is not currently a
robust algorithm in place to identify patients with moder-
ate RA who are at greater risk of disease progression;
therefore, further work is required to develop clinical deci-
sion rules to identify these patients. A real-world evidence
study would be the preferred approach here, assessing a
combination of prognostic factors that could be used to
develop a predictive tool for clinical use.
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